HD-OPM Archive
Hashtags

#science

5 posts

Pelacarsen and ziltivekimab lowered their targets but not events, and why that matters

Nov 08, 2026 · Louis Nervegna ♥ 8 · 💬 6 Lp(a)

Louis shares a physician's commentary on the Lp(a) and inflammation trials presented at AHA: one drug lowered Lp(a) nearly 80% and another sharply cut inflammation, yet event rates matched placebo. The lesson is that measuring and changing a marker does not guarantee benefit, and that the underlying risk factors still matter.